ARW Edit Headshot 2

Anna Rose Welch





Anna Rose Welch is the editorial and community director of Advancing RNA. In this role, she is forging close relationships with the leading voices and organizations in the RNA industry. In addition to penning thought leadership articles and developing other creative forms of content on the evolving RNA industry, she hosts panel discussions and is an active participant in the RNA/ATMP conferences circuit.

Prior to entering the advanced therapies space, Anna Rose built a global editorial following as the Chief Editor of Biosimilar Development.

Over the past decade, her work in the biologics and advanced therapies spaces has taken her across the world to chair conferences, give presentations, moderate panel discussions, and serve on conference advisory boards. Most notably, she has been involved with the BioPhorum ATMP Conference, Phacilitate’s RNA Connect, the AGC CDMO Summit, the World Vaccine Congress, DIA Biosimilars Conference, and the U.S. Chamber of Commerce Annual Healthcare Summit. In 2018, the trade association Grupo FarmaBrasil invited her to Brazil where she addressed members of the Brazilian Ministry of Health, ANVISA, and local biologics and biosimilar manufacturers on establishing national biologics and biosimilar policies.

In 2018, her first book of poetry, We, The Almighty Fires, was published by Alice James Books. She lives in Erie, PA, where she is a violinist in the Presque Isle Pro Musica chamber orchestra and an aspiring ballet dancer.

ARTICLES BY ANNA ROSE

  • R&D
    A Glimpse Into Thailand's Ongoing Life Sciences Transformation
    5/18/2017

    During my visit to Thailand, I was privy, not only to the particularly innovative research goals being pursued, but also to a number of challenges the country has recognized and hopes to address within the next few years to encourage a stronger, more diverse industry.

  • R&D
    What Thailand Revealed About U.S. Pharma R&D
    5/16/2017

    A few weeks ago, I was invited by the Thailand Board of Investment to attend a media trip to learn about the country’s budding life sciences industry. Entering Thailand, a country in which the government is pushing more investment and education in the sciences, was even more striking and meaningful to me given the current scientific climate in the U.S.

  • Biosimilar industry
    Top 5 Biosimilar Developments Of 2016
    12/29/2016

    In the spirit of this list-making season, I compiled what I thought were the five most important biosimilar-related triumphs in the past year. Many of these events were widely covered by the media and will play an influential role in how the biosimilar industry unfolds through 2017 and beyond.

  • biosimilar industry
    The Case For Moving The EMA To Ireland
    12/13/2016

    Relocating an organization as large as the EMA, which employs upwards of 1,000 people in London, will be no easy feat. As such, IDA Ireland, an agency that supports companies in Ireland and promotes foreign direct investments in the country, is working to compile information on why Ireland would be a good location for the EMA.

  • biosimilar industry
    Will Teva's Play Usher Generic, Biosimilar Makers Into “Innovator” Territory?
    7/7/2016

    PhRMA is facing a controversial, potentially industry-altering decision. The generics king Teva has requested to become a member of the trade organization that traditionally represents “innovators”. Could this move redefine the industry's perception of "innovation"?

  • Biosimilar industry
    What Biosimilars Can Learn From The Diamond Industry
    7/5/2016

    Not only are there some fascinating parallels between the fledging biosimilar and lab-grown diamond industries, but there are also some lessons biosimilar makers can take away from the development and commercialization of lab-grown diamonds.

  • drug pricing
    Could Value-Based Pricing Be Yet Another Roadblock To Biosimilar Uptake?
    3/3/2016

    As pay-for-performance drugs becomes more high-profile in the U.S., these emerging deals pose a number of difficulties for reference makers. But if pay-for-performance becomes more wide-spread, could innovators' successes become yet another roadblock to getting biosimilars into doctor's treatment repertoire and patients' hands?

  • EPIRUS Biopharmaceuticals: What Biosimilars Can Learn From The Generics Market
    EPIRUS Biopharmaceuticals: What Biosimilars Can Learn From The Generics Market
    1/12/2016

    Though differentiating large-molecule biosimilars from small molecule generics is a staple in biosimilar education, Amit Munshi, CEO of pure-play biosimilar company EPIRUS Biopharmaceuticals, argues the history of the generics market could hold valuable clues as to how the biosimilar market will evolve.

  • generic drugs
    The Generic And Biosimilar Markets: Are They Really That Different?
    10/19/2015

    As the FDA continues to compose guidances on the labeling and interchangeability of biosimilar medicines, there remains one big, overarching concern in the industry, and that is making sure biosimilar medicines are not treated as small molecule generics. But should we really be considering the two types of drugs as drastically different as we have been over the past few months?

  • drug approvals
    Could 96 Percent FDA Drug Approval Rate Harm Biosimilar Market?
    9/1/2015

    Last week, Matthew Herper of Forbes published an eye-opening article providing a closer look at FDA approvals in recent years, coming to the conclusion that the industry is facing what could be a dangerously high approval rate for new drugs. But how could high approval rates be a bad thing?

More From Anna Rose Welch